New vaccines aim to block malaria transmission in africa
NCT ID NCT06549257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental vaccines designed to stop the malaria parasite from spreading from person to person. The vaccines target the parasite's development inside mosquitoes, so vaccinated people who get bitten are less likely to pass the infection on. The trial involves 56 healthy volunteers aged 5 to 45 in Burkina Faso, and will check for safety and immune responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut des Sciences et Techniques (INSTech)
Bobo-Dioulasso, 01 BP 2779, Burkina Faso
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- Malaria prevention study pulled before it began
- Could targeted drug dosing stamp out malaria in thai hotspots?
- New malaria pill for tiny infants studied, but trial stopped early
- Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial
- Half-Dose malaria vaccine could double protection for millions